HCW 9218
Alternative Names: Bifunctional TGF-β antagonist/IL-15 protein complex - HCW Biologics; HCW-9218Latest Information Update: 10 Jun 2024
At a glance
- Originator HCW Biologics
- Developer HCW Biologics; University of Minnesota
- Class Antineoplastics; Hepatoprotectants; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 15 replacements; Transforming growth factor beta type II receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer
- Phase I/II Pancreatic cancer
- Phase I Solid tumours
- Research Fibrosis; Liver cancer; Neurodegenerative disorders; Non-alcoholic fatty liver disease
- Discontinued Lymphoma; Malignant melanoma; Pulmonary fibrosis
Most Recent Events
- 15 May 2024 HCW Biologics in collaboration with University of Pittsburgh Medical Center plans a phase II trial for Ovarian cancer (Late-stage disease, Metastatic disease, Combination therapy, Neoadjuvant therapy) in the second half of 2024
- 15 May 2024 HCW Biologics announces intention to submit an Investigational New Drug (IND) application for Autoimmune disorders in the third quarter of 2024
- 15 May 2024 HCW Biologics plans a clinical trial for an Autoimmune disorders